Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 3:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo Formulation 1 Clear all
Completed Phase 4 Interventional

Polyherbal Capsule Formulation for Joint Health

NCT02157701
View directory record Official record
Conditions
Knee Discomfort, Pain Physical Activity
Interventions
Polyherbal capsule, Placebo capsule
Dietary Supplement
Lead sponsor
NewChapter, Inc.
Industry
Eligibility
25 Years to 75 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Homestead, Florida • Duncansville, Pennsylvania • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2015 · Synced Sep 17, 2026, 3:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety & Efficacy of True Human Antibody, 514G3, in Staphylococcus Aureus Bacteremia Hospitalized Subjects.

NCT02357966
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia
Interventions
514G3 (2 mg/kg) plus standard IV antibiotic treatment, 514G3 (10 mg/kg) plus standard IV antibiotic treatment, 514G3 (40 mg/kg) plus standard IV antibiotic treatment, Placebo plus standard IV antibiotic treatment, 514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase II, Placebo plus standard IV antibiotic treatment: Phase II
Biological · Other
Lead sponsor
XBiotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Columbus, Georgia • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 17, 2026, 3:19 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older

NCT06686654
View directory record Official record
Conditions
Human Metapneumovirus Immunization, Respiratory Syncytial Virus Immunization
Interventions
Investigational hMPV/RSV vaccine, Investigational hMPV vaccine (monovalent), Investigational RSV vaccine (monovalent), Licensed RSV Vaccine, Placebo, Investigational RSV+hMPV vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
60 Years and older
Enrollment
1,530 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
24
States / cities
Phoenix, Arizona • Garden Grove, California • Gardena, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Sep 17, 2026, 3:19 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS)

NCT03154333
View directory record Official record
Conditions
Epidermolysis Bullosa Simplex
Interventions
diacerein 1% ointment, A placebo ointment
Drug
Lead sponsor
Castle Creek Pharmaceuticals, LLC
Industry
Eligibility
4 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
12
States / cities
Phoenix, Arizona • Palo Alto, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Sep 17, 2026, 3:19 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Gastroesophageal Reflux Disease

NCT00321984
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Dexlansoprazole MR, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
947 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
153
States / cities
Alabaster, Alabama • Birmingham, Alabama • Hueytown, Alabama + 150 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2011 · Synced Sep 17, 2026, 3:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Comparison of the Safety and Immunogenicity of Various Schedules of Dengue Vaccine in Healthy Adult Volunteers

NCT01542632
View directory record Official record
Conditions
Healthy
Interventions
Takeda's Tetravalent Dengue Vaccine Candidate (TDV), TDV New Formulation, Placebo, New Formulation Placebo
Biological · Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 45 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
3
States / cities
Fort Collins, Colorado • Galveston, Texas • West Jordan, Utah
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Sep 17, 2026, 3:19 PM EDT
Completed Phase 2 Interventional Results available

LACTIN-V Study for Recurrent Bacterial Vaginosis

NCT02766023
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Lactobacillus crispatus CTV-05, Metronidazole, Placebo
Biological · Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
4
States / cities
San Diego, California • San Francisco, California • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Sep 17, 2026, 3:19 PM EDT
Active, not recruiting Phase 2 Interventional

Trial of Cannabidiol to Treat Severe Behavior Problems in Children With Autism

NCT04517799
View directory record Official record
Conditions
Autism, Autism Spectrum Disorder
Interventions
Epidiolex, placebo oral solution
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
7 Years to 14 Years · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 17, 2026, 3:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of a Single Vaccination of One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) and a Single Dose Level of a 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) in Healthy Adults Aged 65 to <86 Years

NCT01643941
View directory record Official record
Conditions
Staphylococcal Infections
Interventions
SA4Ag vaccine low dose, Blood draw, Colonization swab sample, SA4Ag vaccine mid dose, SA4Ag vaccine high dose, SA3Ag vaccine, Blood sample, Placebo, Colonization swab samples
Biological · Procedure
Lead sponsor
Pfizer
Industry
Eligibility
65 Years to 85 Years
Enrollment
284 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
7
States / cities
Hollywood, Florida • South Miami, Florida • Overland Park, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2019 · Synced Sep 17, 2026, 3:19 PM EDT
Not listed Early Phase 1 Interventional

Pilot Study of the IL-1 Antagonist Anakinra for the Treatment of Endometriosis Related Symptoms

NCT03991520
View directory record Official record
Conditions
Endometriosis, Anakinra, Markers of Inflammation
Interventions
Anakinra 100Mg/0.67Ml Inj Syringe, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Sep 17, 2026, 3:19 PM EDT
Recruiting Phase 2 Interventional

Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.

NCT06450925
View directory record Official record
Conditions
Graft Vs Host Disease, Vitamin A Deficiency, Vitamin D Deficiency
Interventions
Vitamin A, Placebo
Drug · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Tampa, Florida • Buffalo, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 17, 2026, 3:19 PM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

NCT06463587
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
Placebo, Cladribine Low Dose, Cladribine High Dose
Other · Drug
Lead sponsor
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Industry
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
21
States / cities
Phoenix, Arizona • Longmont, Colorado • Farmington, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 17, 2026, 3:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects

NCT03820414
View directory record Official record
Conditions
Herpes Zoster, Varicella Zoster
Interventions
CRV 101, Placebo
Biological
Lead sponsor
Curevo Inc
Industry
Eligibility
18 Years to 49 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Sep 17, 2026, 3:19 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairment and Insulin Resistance

NCT07220694
View directory record Official record
Conditions
Insulin Resistance, Mild Cognitive Impairment, Cognitive Decline, Neurodegenerative Disorders
Interventions
Sabroxy®, Placebo
Dietary Supplement · Other
Lead sponsor
SF Research Institute, Inc.
Network
Eligibility
40 Years to 80 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 17, 2026, 3:19 PM EDT
Completed Phase 3 Interventional Results available

A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I)

NCT00317642
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
clofarabine (IV formulation), placebo, cytarabine
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
55 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
41
States / cities
Scottsdale, Arizona • Tucson, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2014 · Synced Sep 17, 2026, 3:19 PM EDT
Completed Not applicable Interventional

Dose-Response Study to Evaluate the Effect of BKR-017 on Insulin Resistance and Other Metabolic Parameters in Type 2 Diabetes Patients

NCT04673656
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
BKR-017
Dietary Supplement
Lead sponsor
BioKier Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Baton Rouge, Louisiana • Durham, North Carolina • Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Sep 17, 2026, 3:19 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Dosing Interval Study of SST-0225 Topical Ibuprofen Cream in the Treatment of Delayed Onset Muscle Soreness

NCT02339129
View directory record Official record
Conditions
Delayed Onset Muscle Soreness
Interventions
SST-0225, Placebo
Drug
Lead sponsor
Strategic Science & Technologies, LLC
Industry
Eligibility
16 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
South Miami, Florida • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 8, 2016 · Synced Sep 17, 2026, 3:19 PM EDT
Completed Phase 3 Interventional Results available

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)

NCT01908829
View directory record Official record
Conditions
Urinary Bladder Diseases, Urinary Bladder Overactive, Urologic Diseases
Interventions
mirabegron 25 mg, mirabegron 50 mg, solifenacin 5 mg, solifenacin 10 mg, mirabegron 25 mg matching placebo, mirabegron 50 mg matching placebo, solifenacin 5 mg matching placebo, solifenacin 10 mg matching placebo
Drug
Lead sponsor
Astellas Pharma Europe Ltd.
Industry
Eligibility
18 Years and older
Enrollment
2,174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
36
States / cities
Tucson, Arizona • Buena Park, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Sep 17, 2026, 3:19 PM EDT
Completed Phase 1 Interventional Results available

28-Day Daily-dose Crossover Study of the Safety and Tolerability of SB-121 (Lactobacillus Reuteri With Sephadex® and Maltose) in Subjects, Ages 15 to 45 Years, Diagnosed With Autistic Disorder

NCT04944901
View directory record Official record
Conditions
Autistic Disorder
Interventions
SB-121, Placebo
Drug
Lead sponsor
Scioto Biosciences, Inc.
Industry
Eligibility
15 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 24, 2024 · Synced Sep 17, 2026, 3:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers

NCT04725877
View directory record Official record
Conditions
HIV I Infection
Interventions
VIR-1111, Placebo
Biological · Drug
Lead sponsor
Vir Biotechnology, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
3
States / cities
Miami, Florida • Seattle, Washington • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 26, 2023 · Synced Sep 17, 2026, 3:19 PM EDT
Completed Phase 3 Interventional Results available

A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Naturalistic Setting

NCT02520388
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
HLD200 methylphenidate hydrochloride (MPH) Capsules, Placebo
Drug
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Other
Eligibility
6 Years to 12 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
21
States / cities
Newport Beach, California • Bradenton, Florida • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Sep 17, 2026, 3:19 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients

NCT01567527
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
Intramuscular (IM) Depot Aripiprazole, Intramuscular (IM) Depot Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
731 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
42
States / cities
Birmingham, Alabama • Springdale, Arkansas • Beverly Hills, California + 39 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2018 · Synced Sep 17, 2026, 3:19 PM EDT
Terminated Phase 2 Interventional Results available

Study of URG101 in Painful Bladder Syndrome and Interstitial Cystitis

NCT00517868
View directory record Official record
Conditions
Painful Bladder Syndrome, Interstitial Cystitis, Bladder Pain Syndrome
Interventions
URG101, Placebo
Drug
Lead sponsor
Urigen
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
6
States / cities
Glendora, California • San Diego, California • Cartersville, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Sep 17, 2026, 3:19 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older

NCT00985088
View directory record Official record
Conditions
Influenza
Interventions
GSK2340274A, GSK2340273A, Saline placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
1,343 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
10
States / cities
Huntsville, Alabama • Jacksonville, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Sep 17, 2026, 3:19 PM EDT